Literature DB >> 17919181

A transgenic model to study the pathogenesis of somatic mtDNA mutation accumulation in beta-cells.

K G Bensch1, W Degraaf, P A Hansen, H P Zassenhaus, J A Corbett.   

Abstract

Low levels of somatic mutations accumulate in mitochondrial DNA (mtDNA) as we age; however, the pathogenic nature of these mutations is unknown. In contrast, mutational loads of >30% of mtDNA are associated with electron transport chain defects that result in mitochondrial diseases such as mitochondrial encephalopathy lactic acidosis and stroke-like episodes. Pancreatic beta-cells may be extremely sensitive to the accumulation of mtDNA mutations, as insulin secretion requires the mitochondrial oxidation of glucose to CO(2). Type 2 diabetes arises when beta-cells fail to compensate for the increased demand for insulin, and many type 2 diabetics progress to insulin dependence because of a loss of beta-cell function or beta-cell death. This loss of beta-cell function/beta-cell death has been attributed to the toxic effects of elevated levels of lipids and glucose resulting in the enhanced production of free radicals in beta-cells. mtDNA, localized in close proximity to one of the major cellular sites of free radical production, comprises more than 95% coding sequences such that mutations result in changes in the coding sequence. It has long been known that mtDNA mutations accumulate with age; however, only recently have studies examined the influence of somatic mtDNA mutation accumulation on disease pathogenesis. This article will focus on the effects of low-level somatic mtDNA mutation accumulation on ageing, cardiovascular disease and diabetes.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17919181     DOI: 10.1111/j.1463-1326.2007.00776.x

Source DB:  PubMed          Journal:  Diabetes Obes Metab        ISSN: 1462-8902            Impact factor:   6.577


  7 in total

Review 1.  Mitochondrial DNA replication and disease: insights from DNA polymerase γ mutations.

Authors:  Jeffrey D Stumpf; William C Copeland
Journal:  Cell Mol Life Sci       Date:  2010-10-08       Impact factor: 9.261

2.  Mitochondrial DNA deletions in mice in men: substantia nigra is much less affected in the mouse.

Authors:  Xinhong Guo; Elena Kudryavtseva; Natalya Bodyak; Alexander Nicholas; Igor Dombrovsky; Deye Yang; Yevgenya Kraytsberg; David K Simon; Konstantin Khrapko
Journal:  Biochim Biophys Acta       Date:  2010-04-11

Review 3.  Potential therapeutic benefits of strategies directed to mitochondria.

Authors:  Amadou K S Camara; Edward J Lesnefsky; David F Stowe
Journal:  Antioxid Redox Signal       Date:  2010-08-01       Impact factor: 8.401

Review 4.  Mouse models of oxidative phosphorylation defects: powerful tools to study the pathobiology of mitochondrial diseases.

Authors:  Alessandra Torraco; Francisca Diaz; Uma D Vempati; Carlos T Moraes
Journal:  Biochim Biophys Acta       Date:  2008-06-13

Review 5.  Role of the mitochondrial DNA replication machinery in mitochondrial DNA mutagenesis, aging and age-related diseases.

Authors:  Karen L DeBalsi; Kirsten E Hoff; William C Copeland
Journal:  Ageing Res Rev       Date:  2016-04-30       Impact factor: 10.895

Review 6.  Mitochondrial DNA mutations and aging: devils in the details?

Authors:  Konstantin Khrapko; Jan Vijg
Journal:  Trends Genet       Date:  2008-12-26       Impact factor: 11.639

7.  Do mtDNA deletions drive premature aging in mtDNA mutator mice?

Authors:  Yevgenya Kraytsberg; David K Simon; Douglas M Turnbull; Konstantin Khrapko
Journal:  Aging Cell       Date:  2009-04-22       Impact factor: 9.304

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.